Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Therapy Pathways in the Treatment of Hormone Naive Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormon-Releasing-Hormon (LHRH) Agonists. (ProComD)

Next Previous
Trial Profile

Therapy Pathways in the Treatment of Hormone Naive Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormon-Releasing-Hormon (LHRH) Agonists. (ProComD)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Degarelix (Primary) ; Buserelin; Goserelin; Leuprorelin; Triptorelin
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms ProComD
  • Sponsors Ferring Pharmaceuticals

Most Recent Events

  • 01 Jul 2019 Status changed from active, no longer recruiting to completed.
  • 10 Jan 2019 Planned End Date changed from 1 Dec 2020 to 1 Jun 2019.
  • 10 Jan 2019 Planned primary completion date changed from 1 Dec 2020 to 1 Jun 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top